Projects

The German Consortium for Hereditary Breast and Ovarian Cancer HBOC has been founded in 1996 by the German Cancer Aid and has been funded by the German Cancer Aid until recently. GC-HBOC currently comprises 17 university centers providing genetic counseling, histopathological and molecular tissue analysis, genetic testing, and specific structured surveillance programs for early cancer detection at each clinical unit, all based on defined standard operating procedures.

The German Consortium for Hereditary Non-Polyposis Colorectal Cancer has been founded in 1999 by the German Cancer Aid and has been funded by the German Cancer Aid until recently. GC-HNPCC currently comprises 6 university centers providing genetic counseling, histopathological and molecular tissue analysis, genetic testing, and specific structured surveillance programs for early cancer detection at each clinical unit, all based on defined standard operating procedures.

The group is interested in omic-level studies including the genome, methylome, transcriptome, and metabolome of the general population as well as of various diseases including cardiovascular diseases, pneumonia, sepsis, obesity, and brain cancers. Additionally, we aim at transfering results of biomathematical model simulations into clinical practice e.g. by haematopoietic growth-factor opimization during cytotoxic chemotherapy and optimization of EPO applications in chronic kidney disease.

The ...

During 2004 and 2012 the german cancer aid supported the german glioma network (GGN). The GGN is a consortium where university hospitals with clinical focus in neuro-oncology, reference centers for neuroradiology, neuropathology, molecular diagnostics and biometry cooperate. Thanks to the long-term support it was possible to build a network of competence centers for the treatment of brain tumors in Germany wich is characterized by a interdisciplinary collaboration of all specialist disciplines ...

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study ...

TitleGranulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicentre randomized trialCoordinating investigator:Prof. Dr. Thomas BergSektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum LeipzigSponsorUniversität Leipzig Ritterstr. 26, 04109 LeipzigEudraCT: 2015-002212-32ClinicalTrials.gov: NCT02669680

Gastric cancer (GC) is a complex disease that represents the fifth most common malignancy in the world and the third leading cause of cancer death in both sexes. GC shows a high level of heterogeneity as well as a marked gender difference in incidence, GC affecting twice as many men as women. Chemotherapy (Ct) combined with surgery represents the standard of care for stages II-III GC, but the efficacy of such treatments is still limited for many patients. It is mandatory to develop novel therapeutic ...